Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 4:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 93 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Dabigatran Etexilate Clear all
Terminated Phase 4 Interventional Results available

Dabigatran's Effect on Changes in Atrial Fibrosis in Patients With Atrial Fibrillation

NCT01546883
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Dabigatran etexilate (Pradaxa)
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Oct 8, 2026, 4:27 PM EDT
Recruiting Phase 3 Interventional

Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

NCT04045665
View directory record Official record
Conditions
Atrial Fibrillation, Stroke, Bleeding
Interventions
Antiplatelet-only strategy, Oral Anticoagulant plus background antiplatelet therapy
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
3,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
51
States / cities
Little Rock, Arkansas • Los Angeles, California • Stanford, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 8, 2026, 4:27 PM EDT
Completed Not applicable Interventional Results available

AMPLATZER Cardiac Plug Clinical Trial

NCT01118299
View directory record Official record
Conditions
Atrial Fibrillation, Ischemic Stroke, Peripheral Thromboembolism
Interventions
AMPLATZER Cardiac Plug
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
18
States / cities
Los Angeles, California • Aurora, Colorado • Littleton, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2020 · Synced Oct 8, 2026, 4:27 PM EDT
Recruiting Not applicable Interventional

Perioperative Anticoagulant Use for Surgery Evaluation -2 (PAUSE-2) Study Patients Receiving a Direct Oral Anticoagulant (DOACs-Dabigatran, Rivaroxaban, Apixaban or Edoxaban) and Needing Elective High-Bleed-Risk Surgery or an Invasive Procedure

NCT06957366
View directory record Official record
Conditions
Atrial Fibrillation (AF), VTE
Interventions
PAUSE Perioperative DOAC Management, ASRA Perioperative DOAC Management
Other
Lead sponsor
McMaster University
Other
Eligibility
18 Years and older
Enrollment
920 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
Hartford, Connecticut • Evanston, Illinois • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated May 9, 2025 · Synced Oct 8, 2026, 4:27 PM EDT
Completed No phase listed Observational

Clinical and Economic Outcomes of Oral Anticoagulants in Non-valvular Atrial Fibrillation

NCT03087487
View directory record Official record
Conditions
Non-Valvular Atrial Fibrillation
Interventions
Not listed
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
466,991 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Oct 8, 2026, 4:27 PM EDT
Completed No phase listed Observational Results available

RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism

NCT02596230
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Not listed
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
7,797 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
19
States / cities
Long Beach, California • Miami, Florida • Pembroke Pines, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2020 · Synced Oct 8, 2026, 4:27 PM EDT
Withdrawn Not applicable Interventional

Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF

NCT04684212
View directory record Official record
Conditions
Atrial Fibrillation, Left Atrial Appendage Thrombosis, CVA
Interventions
LAmbre PlusTM Left Atrial Appendage Closure System, Market approved oral anticoagulation (OAC), such as warfarin (Coumadin), dabigatran (Pradaxa), rivaroxaban (Xarelto), apixiban (Eliquis), edoxaban (Savaysa), or betrixaban (Bevyxxa)
Device · Drug
Lead sponsor
Brian O'Neill MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 8, 2026, 4:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants

NCT05347979
View directory record Official record
Conditions
Cushing Syndrome, Neoplasms
Interventions
Dabigatran Etexilate, Relacorilant
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Oct 8, 2026, 4:27 PM EDT
Recruiting No phase listed Observational

Registry of Patients Prescribed Anticoagulation

NCT03504007
View directory record Official record
Conditions
Acute Deep Vein Thrombosis, Acute Pulmonary Embolism
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2033
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 8, 2026, 4:27 PM EDT
Completed No phase listed Observational Results available

Validation of Predictors of OAC Initiation Using EMR Data

NCT03006341
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Dabigatran etexilate, Warfarin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
140,187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 22, 2019 · Synced Oct 8, 2026, 4:27 PM EDT
Withdrawn No phase listed Observational

Dabigatran Versus Warfarin Anticoagulation Before and After Catheter Ablation for the Treatment of Atrial Fibrillation

NCT01607359
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Not listed
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated May 11, 2023 · Synced Oct 8, 2026, 4:27 PM EDT
Completed No phase listed Observational Results available

Management of Gastrointestinal and Urogenital (GI/GU) Bleedings in Atrial Fibrillation Patients Using Pradaxa

NCT02022020
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Not listed
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
16
States / cities
Aurora, Colorado • New Britain, Connecticut • Orlando, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Oct 8, 2026, 4:27 PM EDT
Terminated Phase 4 Interventional Results available

Combined Use of BIOTRONIK Home Monitoring and Predefined Anticoagulation to Reduce Stroke Risk

NCT00559988
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter, Stroke, Embolism, Systemic Arterial, Major Bleeding
Interventions
Home Monitoring Guided OAC, Physician-Directed OAC
Drug
Lead sponsor
Biotronik, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,718 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
73
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Anaheim, California + 70 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Oct 8, 2026, 4:27 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates

NCT04764851
View directory record Official record
Conditions
Drug-Interactions
Interventions
ecopipam HCl ~2mg/kg/day, Cohort 1 Probe Cocktail, Cohort 2 Probe Cocktail, Cohort 3 Probe Cocktail
Drug · Combination Product
Lead sponsor
Emalex Biosciences Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 24, 2021 · Synced Oct 8, 2026, 4:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects

NCT04809818
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
LT3001 drug product, Placebo, Aspirin, Clopidogrel, Apixaban, Dabigatran
Drug
Lead sponsor
Lumosa Therapeutics Co., Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 8, 2026, 4:27 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

A Study of the Effect of Quizartinib on the Pharmacokinetics of the P-gp Substrate Dabigatran Etexilate in Healthy Participants

NCT04459585
View directory record Official record
Conditions
Healthy Subjects, Drug-drug Interaction, Pharmacokinetics, Quizartinib
Interventions
Dabigatran Etexilate Mesylate, Quizartinib
Drug
Lead sponsor
Daiichi Sankyo Co., Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2021 · Synced Oct 8, 2026, 4:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Effect of Co-Administration of AZD9833 on the Pharmacokinetics of Midazolam, of Omeprazole, of Celecoxib and of Dabigatran Etexilate in Healthy Postmenopausal Female Volunteers

NCT05438303
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AZD9833, Midazolam, Omeprazole, Dabigatran Etexilate, Celecoxib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
50 Years to 70 Years · Female only
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Long Beach, California • Berlin, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 12, 2023 · Synced Oct 8, 2026, 4:27 PM EDT
Completed No phase listed Observational

Prospective Study on the Treatment of Unsuspected Pulmonary Embolism in Cancer Patients

NCT01727427
View directory record Official record
Conditions
Unsuspected Pulmonary Embolism
Interventions
Heparin, fondaparinux, vitamin-K antagonists, aspirin
Drug
Lead sponsor
G. d'Annunzio University
Other
Eligibility
18 Years and older
Enrollment
695 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 8, 2019 · Synced Oct 8, 2026, 4:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Interaction of Two HIV Medications With Blood Clot Medications in Healthy Volunteers

NCT01896622
View directory record Official record
Conditions
HIV
Interventions
Ritonavir, Cobicistat
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 8, 2026, 4:27 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Heparin Requirements in Patients Undergoing Atrial Fibrillation Ablation on Coumadin vs NOACs

NCT03520868
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Monitoring Anti Factor Xa level
Diagnostic Test
Lead sponsor
Steward St. Elizabeth's Medical Center of Boston, Inc.
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Brighton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 16, 2021 · Synced Oct 8, 2026, 4:27 PM EDT
Completed Not applicable Interventional Results available

Post-thrombotic Syndrome & Predictors of Recurrence in Catheter-related Thrombosis

NCT01999179
View directory record Official record
Conditions
Venous Thrombosis, Neoplasms
Interventions
Heparin, Low-Molecular-Weight, or direct oral anticoagulants
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
3
States / cities
Minneapolis, Minnesota • Columbus, Ohio • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 18, 2022 · Synced Oct 8, 2026, 4:27 PM EDT
Completed Phase 3 Interventional Results available

Safety of Dabigatran Etexilate in Blood Clot Prevention in Children

NCT02197416
View directory record Official record
Conditions
Venous Thromboembolism, Secondary Prevention
Interventions
dabigatran etexilate
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
Up to 18 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
9
States / cities
Sacramento, California • Miami, Florida • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2020 · Synced Oct 8, 2026, 4:27 PM EDT
Completed Phase 2 Interventional Results available

RE-DEEM Dose Finding Study for Dabigatran Etexilate in Patients With Acute Coronary Syndrome

NCT00621855
View directory record Official record
Conditions
Coronary Disease
Interventions
placebo, dabigatran etexilate
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,878 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Clearwater, Florida
Source: ClinicalTrials.gov public record
Updated Mar 12, 2014 · Synced Oct 8, 2026, 4:27 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Replication of the RELY Anticoagulant Trial in Healthcare Claims Data

NCT04593043
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Warfarin, Dabigatran
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
78,140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 8, 2026, 4:27 PM EDT